February 2023 - BioMedWire (BMW)

TuesdayFeb 28, 2023 12:50 pm

Researchers Find Balancing Ability May Predict Risk of Cognitive Decline

Investigators at the University of Tsukuba have discovered that physical balance can be used to predict an individual's risk of mild cognitive impairment and Alzheimer’s disease (AD). The researchers found that physicians may be able to identify patients who have higher chances of developing the neurological disease by measuring their physical balance. Alzheimer’s disease is usually precipitated by mild cognitive impairment, a condition that results in a minor decline in cognitive function. This stage of cognitive decline is characterized by problems with memory, judgment or language and is usually followed by severe cognitive decline if left untreated. Given that the…

MondayFeb 27, 2023 12:24 pm

Risk Factors of Age-Related Macular Degeneration

Age-related macular generation is an ocular disease that causes a reduction in central vision as individuals grow older. The condition is caused when a region of the retina called the macular becomes damaged and causes patients to lose the ability to see fine details; it can also be referred to as central vision. While age-related macular degeneration (ARMD) rarely causes blindness, it is the number one cause of severe eyesight loss in people aged 50 and above. Individuals suffering from the advanced stages of this ailment often lose the ability to see faces, drive and read the small print. By…

FridayFeb 24, 2023 11:05 am

Study Finds Eczema Cases Increasing Among Children

Eczema is a condition that causes an individual’s skin to become dry, itchy and cracked; in some cases, skin can even ooze. Some types of eczema, such as dyshidrotic eczema, can cause blisters. Data from the National Eczema Association indicates more than 31 million individuals in the U.S. suffer from eczema. While it can flare up at any age, this chronic skin condition is common in young children. It is estimated that about 9.6 million children below 18 years of age suffer from atopic dermatitis. Experts believe that this skin condition is more prevalent in higher-income areas, which are more…

FridayFeb 24, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical studies So far, the preclinical studies have shown that the NanoAb results in significantly milder illness and faster recovery, eliminates the SARS-CoV-2 virus from the lungs, and prevents illness when administered prophylactically The FDA has revoked the authorization of multiple mAb treatments and one mAb prophylactic drug, creating a significant gap in a market that has shown strong demand for COVID-19 treatments BiondVax is…

ThursdayFeb 23, 2023 2:14 pm

Researchers Find Ways to Ease Cancer Treatment Outcome Prediction

Immunotherapy is one of the newest cancer treatment options that has made it possible for physicians to target and treat cancer more effectively. This treatment works by helping a patient’s immune system to kill cancer cells rather than using pharmaceuticals or radiation therapy to directly fight the cancer cells. Immunotherapy typically has fewer side effects compared to other cancer treatment options, and it can be used on cancers such as skin cancer, which don’t respond well to other treatments, including chemotherapy, and it may prevent cancer from returning by boosting the immune system’s ability to fight cancer cells. However, immunotherapies…

WednesdayFeb 22, 2023 11:24 am

Consuming Too Much Salt May Trigger Autoimmune Illnesses

Consuming too much salt affects an individual’s cardiovascular system and blood pressure negatively while also impacting the immune system adversely. A new study has now found that the consumption of too much salt weakens the energy supply of regulatory T cells, preventing them from working properly. Regulatory T cells are cells that help maintain homeostasis in the body by suppressing immune responses that may cause excessive inflammation. The study was carried out by a global team of researchers coordinated by researchers at the Max Delbrück Center in Germany, Hasselt University and the VIB Center for Inflammation Research in Belgium. A…

WednesdayFeb 22, 2023 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The…

WednesdayFeb 22, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) NanoAb Product Shows Preclinical Promise as COVID Preventative for consumers Hit by Evusheld’s EUA Withdrawal

BiondVax Pharmaceuticals is promoting preclinical results of its lead “biobetter” NanoAb drug candidate for conveniently proactively preventing COVID The company’s CEO recently presented the data at the annual BIO CEO & Investor Conference in New York, as well as updates on the company’s pipeline for treating autoimmune diseases such as psoriasis, asthma, psoriatic arthritis and macular degeneration Monoclonal antibody-based drug product Evusheld recently lost its EUA authorization as a COVID preventative after FDA findings that it insufficiently protects against the current wOmicron sub-variants, eliminating the only preventative option for vaccine-intolerant patients BiondVax nano-sized antibodies may provide superior responses to COVID…

TuesdayFeb 21, 2023 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Supports American Heart Month with Commitment to Provide Solutions

President Biden proclaims February as American Heart Month Annual tradition provides opportunity to focus on nationwide problem of heart and blood-vessel diseases HeartBeam is committed to being part of the solution for identifying, treating heart attacks Following a decades-long tradition, President Joseph Biden issued a proclamation from the White House declaring February as American Heart Month (https://ibn.fm/6Z9Iq). This nationwide focus on heart health is fully supported by HeartBeam (NASDAQ: BEAT), a cardiac technology company dedicated to leading the way in finding effective ways to detect heart attacks earlier than ever before. “During American Heart Month, we recommit to supporting the…

TuesdayFeb 21, 2023 11:41 am

Research Highlights How Gender Pain Gap Keeps Women from Receiving Adequate Healthcare

A recently conducted survey has highlighted a clear disparity regarding the perceptions and experiences of pain in women and men. The survey, which involved more than 5,000 individuals aged between 18 and 65 year old, found that about 50% of women did not receive needed support from their general practitioners when they tried getting help for their pain. This proportion is quite high, especially when compared to the 36% of men who experienced the same. Roughly 63% of women also revealed that they felt men’s pain was deemed more serious because of gender discrimination by healthcare professionals. Additionally, more than…